Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Vania HungriaPawel RobakMarek HusVera ZherebtsovaChristopher WardP Joy HoAna Carolina Ribas de AlmeidaRoman HajekKihyun KimSebastian GrosickiHanlon SiaAdam BryantMarcelo Pitombeira de LacerdaGracia Aparecida MartinezAnna Maria Sureda BalaríIrwindeep SandhuClaudio CerchionePeter GanlyMeletios DimopoulosChengcheng FuMamta GargAl-Ola AbdallahAlbert OriolMoshe E GattMichele CavoRobert RifkinTomoaki FujisakiMichał MielnikNick PiroozAstrid McKeownSimon McNamaraXiangdong ZhouMaureen NicholsEric LewisRachel RogersHena BaigLydia EccersleySumita Roy-GhantaJoanna OpalinskaMaría-Victoria Mateosnull nullPublished in: The New England journal of medicine (2024)
As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.).